Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.
History In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.
In November 2000, the company became a public company via an initial public offering.
In June 2019, Pfizer acquired the company for approximately $11 billion.
Discovery of FDA Approved Small Molecules
MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics) BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly) RETEVMO (Selpercatinib) - RET inhibitor - Approved 2024, licensed by Loxo Oncology (Eli Lilly) GANOVO (Danoprevir) - HCV Protease inhibitor - Approved 2018 (in China), licensed by Roche
References